Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merus NV MRUS

Healthcare Biotechnology
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's... see more

Recent & Breaking News (NDAQ:MRUS)

Merus to Present at Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Merus Receives FDA extension of PDUFA for zenocutuzumab

GlobeNewswire November 5, 2024

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

GlobeNewswire October 31, 2024

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

GlobeNewswire September 30, 2024

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

GlobeNewswire September 17, 2024

Merus to Present at Canaccord Genuity's 44th Annual Growth Conference

GlobeNewswire August 6, 2024

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire August 1, 2024

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

GlobeNewswire July 24, 2024

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

GlobeNewswire July 8, 2024

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

GlobeNewswire July 1, 2024

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire June 3, 2024

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

GlobeNewswire June 2, 2024

Merus Announces Pricing of Upsized Public Offering of Common Shares

GlobeNewswire May 29, 2024

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Merus N.V. Announces Proposed Public Offering of Common Shares

GlobeNewswire May 28, 2024

Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

GlobeNewswire May 28, 2024

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

GlobeNewswire May 23, 2024

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire May 23, 2024

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

GlobeNewswire May 13, 2024

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire May 8, 2024